US · PHG · MEDICAL - DEVICES
Koninklijke Philips N.V. (PHG) intrinsic value and stock valuation
$28.61as of 2026-11-21 · Mkt cap 25.99B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Koninklijke Philips N.V. DCF and intrinsic value
InvestorsCraft values PHG with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from PHG’s statements →
Koninklijke Philips N.V. Graham Number
Graham Number: $15.46d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Teva Pharmaceutical Industries Limited (TEVA) $39.23
- Natera, Inc. (NTRA) $273.40
- DexCom, Inc. (DXCM) $79.32
- Mettler-Toledo International Inc. (MTD) $1,666.88
- Labcorp Holdings Inc. (LH) $367.13
- BioNTech SE (BNTX) $80.96
- STERIS plc (STE) $255.76
- Zimmer Biomet Holdings, Inc. (ZBH) $101.10
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $17.8B | $18B | $18.2B | $17.8B | $17.2B |
| Operating income | $1.42B | $529M | -$-115M | -$-1.53B | $553M |
| Net income | $895M | -$-702M | -$-466M | -$-1.61B | $3.32B |
| EPSd | $929.9K | -$-752.11K | -$-491.15K | -$-1.69M | $3.49M |
| Operating cash flow | $1.16B | $1.7B | $2.31B | -$-181.82M | $1.93B |
| Capital expenditure | -$-269M | -$-342.9M | -$-371.9M | -$-466.63M | -$-469.25M |
| Free cash flow | $893M | $1.35B | $1.94B | -$-648.45M | $1.46B |
| Total assets | $26.9B | $29B | $29.4B | $30.7B | $31B |
| Total debt | $8.09B | $7.49B | $7.29B | $7.34B | $6.05B |
| Net debt | $5.29B | $5.09B | $5.42B | $6.17B | $3.74B |
| Total equity | $11B | $12B | $12.1B | $13.3B | $14.5B |
| Cash and short-term investments | $2.79B | $2.4B | $1.87B | $1.18B | $2.31B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $17.8B | $18B | $18.2B | $17.8B | $17.2B |
| Cost of revenue | $9.78B | $10.2B | $10.7B | $10.6B | $9.99B |
| Gross profit | $8.06B | $7.77B | $7.45B | $7.19B | $7.17B |
| Research and development expenses | $1.7B | $1.75B | $1.89B | $2.09B | $1.81B |
| Selling, general and administrative expenses | $4.97B | $5.07B | $5.13B | $5.29B | $4.86B |
| Other expenses | -$-36M | $429M | $541M | $1.34B | -$-48M |
| Operating expenses | $6.63B | $7.24B | $7.56B | $8.72B | $6.62B |
| Cost and expenses | $16.4B | $17.5B | $18.3B | $19.4B | $16.6B |
| Interest income | $108.5M | $79M | $46M | $25M | $18M |
| Interest expense | $332.3M | $337M | $306M | $244M | $164M |
| Depreciation and amortization | $1.13B | $1.39B | $1.26B | $1.6B | $1.32B |
| Ebitda | $2.64B | $1.85B | $1.04B | $115M | $2B |
| Operating income | $1.42B | $529M | -$-115M | -$-1.53B | $553M |
| Total other income/expenses, net | -$-242M | -$-406M | -$-412M | -$-202M | -$-44M |
| Income before tax | $1.18B | $123M | -$-527M | -$-1.73B | $509M |
| Income tax expense | $282M | $963M | -$-73M | -$-113M | -$-103M |
| Net income | $895M | -$-702M | -$-466M | -$-1.61B | $3.32B |
| Weighted average shares outstanding | $962.4M | $933.4M | $948.8M | $952.5M | $907.5M |
| Weighted average diluted shares outstanding | $962.5M | $933.4M | $948.8M | $952.5M | $950.3M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $2.79B | $2.4B | $1.87B | $1.18B | $2.31B |
| Net receivables | $3.53B | $3.67B | $4.25B | $4.65B | $4.29B |
| Inventory | $2.87B | $3.2B | $3.49B | $4.05B | $3.45B |
| Total current assets | $9.93B | $10B | $9.94B | $10.3B | $10.3B |
| Property, plant and equipment, net | $2.22B | $2.45B | $2.48B | $2.64B | $2.7B |
| Goodwill and intangible assets | $11.8B | $13.4B | $13.1B | $13.8B | $14.3B |
| Long-term investments | $852M | $889M | $1B | $1.2B | $1.06B |
| Total non-current assets | $17B | $19B | $19.5B | $20.4B | $20.6B |
| Total assets | $26.9B | $29B | $29.4B | $30.7B | $31B |
| Accounts payable | $1.93B | $1.83B | $1.92B | $1.97B | $1.87B |
| Short-term debt | $1.15B | $443M | $334M | $325M | $310M |
| Deferred revenue | $0.00 | $1.7B | $1.81B | $1.7B | $1.49B |
| Total current liabilities | $7.51B | $8.14B | $8.29B | $7.93B | $7.45B |
| Long-term debt | $6.93B | $7.05B | $6.96B | $7.02B | $5.74B |
| Deferred revenue, non-current | $0.00 | $431M | $469M | $515M | $446M |
| Total non-current liabilities | $8.45B | $8.79B | $9.06B | $9.47B | $9.04B |
| Capital lease obligations | $0.00 | $1.07B | $1.08B | $1.08B | $1.22B |
| Total liabilities | $16B | $16.9B | $17.3B | $17.4B | $16.5B |
| Common stock | $193M | $188M | $183M | $178M | $177M |
| Retained earnings | $3.58B | $3.65B | $5.4B | $6.83B | $9.34B |
| Accumulated other comprehensive income (loss) | $274M | $1.93B | $879M | $1.49B | $748M |
| Total equity | $11B | $12B | $12.1B | $13.3B | $14.5B |
| Total investments | $852M | $891M | $1B | $1.21B | $1.06B |
| Total debt | $8.09B | $7.49B | $7.29B | $7.34B | $6.05B |
| Net debt | $5.29B | $5.09B | $5.42B | $6.17B | $3.74B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $895M | -$-912.95M | -$-492.99M | -$-1.7B | $718.6M |
| Depreciation and amortization | $1.13B | $1.26B | $1.39B | $1.26B | $1.24B |
| Stock-based compensation | $141M | $0.00 | $0.00 | $0.00 | $0.00 |
| Change in working capital | -$-1.33B | $7.57M | $1.51B | -$-1.24B | -$-179.66M |
| Accounts receivable | -$-9M | -$-1.08M | $322.2M | -$-359.43M | $0.00 |
| Inventory | -$-115M | $248.8M | $277.9M | -$-601.16M | -$-686.73M |
| Accounts payable | $0.00 | -$-630.63M | $387M | $54.7M | $258.9M |
| Net cash provided by operating activities | $1.16B | $1.7B | $2.31B | -$-181.82M | $1.93B |
| Investments in property, plant and equipment | -$-269M | -$-731.22M | -$-695.16M | -$-847.09M | -$-901.85M |
| Acquisitions, net | -$-3M | $141.7M | $104.9M | -$-600.11M | -$-3.5B |
| Net cash used for investing activities | -$-737M | -$-633.87M | -$-553.53M | -$-1.58B | -$-317.95M |
| Common stock issued | $0.00 | $0.00 | $0.00 | $12.6M | $27.2M |
| Common stock repurchased | $0.00 | -$-444.57M | -$-715.7M | -$-196.53M | -$-1.93B |
| Dividends paid | -$-328M | -$-1.08M | -$-2.16M | -$-433M | -$-569.71M |
| Net cash used for financing activities | $107M | -$-536.52M | -$-916.79M | $525.5M | -$-2.77B |
| Net change in cash | $393M | $421.6M | $813.8M | -$-1.37B | -$-1.33B |
| Cash at end of period | $2.79B | $2.49B | $2.06B | $1.25B | $2.62B |
| Operating cash flow | $1.16B | $1.7B | $2.31B | -$-181.82M | $1.93B |
| Capital expenditure | -$-269M | -$-342.9M | -$-371.9M | -$-466.63M | -$-469.25M |
| Free cash flow | $893M | $1.35B | $1.94B | -$-648.45M | $1.46B |
Line items
Line items
Line items
About Koninklijke Philips N.V.
Koninklijke Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Diagnosis and Treatment; Connected Care; Personal Health; and Other. The Diagnosis and Treatment segment consists of systems, smart devices, software, and services, powered by AI-enabled solutions that support precision diagnoses and minimally invasive treatment in therapeutic areas such as cardiology, peripheral vascular, neurology, surgery, and oncology. The Connected Care segment focuses on Hospital Patient Monitoring, Sleep and Respiratory Care, and Enterprise Informatics. The Personal Health segment represents Oral Healthcare business unit, Personal Care business unit, and Mother and Child Care business unit. The Other segment is involved on the Innovation and Strategy, IP Royalties, Central costs, and other small items. The company was founded by Anton Frederik Philips and Gerard Leonard Frederik Philips in 1891 and is headquartered in Amsterdam, the Netherlands.
- CEO
- Roy Jakobs
- Employees
- 66.4K
- Beta
- 0.92
Explore
Frequently asked questions
What is the intrinsic value of Koninklijke Philips N.V. (PHG)?
Koninklijke Philips N.V. (PHG) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is PHG undervalued?
PHG trades at a price of $28.61 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.